Cash cost of settling New River's stock options and SARs 124.5
Cash cost for settling sold warrants over 4.0 million shares 133.0
of New River's common stock
Direct acquisition costs 61.0
(1) New River entered into this prepaid forward purchase contract with Merrill Lynch in July 2006.
Accounting for the Effective Settlement of the New River Collaboration Agreement
Prior to the acquisition of New River, on January 31, 2005 Shire entered into a collaboration agreement with New River which governed the development, manufacture and commercialisation of VYVANSE for the treatment of ADHD in the US and rest of the world territories. In March 2005, this collaboration agreement was split into two separate agreements, the US Collaboration Agreement and the RoW Territory License Agreement (together the "New River Collaboration Agreements").
Under the terms of the New River Collaboration Agreements, the parties were required to collaborate on the development, manufacturing, marketing and sales of VYVANSE in the US. Profits from the collaboration arising in the US were to be divided according to a predetermined formula, based on the scheduling of VYVANSE by the DEA. Post-approval milestones were due under the New River Collaboration Agreements if the product received favourable scheduling (schedule III, IV or V or unscheduled) and on the achievement of certain sales milestones.
Through the New River Collaboration Agreements Shire also acquired the
license in the RoW territory to develop and commercialise VYVANSE, in
consideration of a low double-digi
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved